Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDEC-C2B8 anti-lymphoma antibody targeting the CD20 antigen on mature B cells and on B cell tumors: Began a single-arm, single-agent Phase III trial in the U.S.

Genentech Inc. (GNE), South San Francisco

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE